1. Lin, P.P.; Pandey, M.K.; Jin, F.; Raymond, A.K.; Akiyama, H.; Lozano, G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009, 30, 1789–1795. [CrossRef]
2. Luetke, A.; Meyers, P.A.; Lewis, I.; Juergens, H. Osteosarcoma treatment—Where do we stand? A state of the art review. Cancer Treat. Rev. 2014, 40, 523–532. [CrossRef] [PubMed]
3. Zhang, C.; Morimoto, L.M.; de Smith, A.J.; Hansen, H.M.; Gonzalez-Maya, J.; Endicott, A.A.; Smirnov, I.V.; Metayer, C.; Wei, Q.; Eward, W.C.; et al. Genetic determinants of childhood and adult height associated with osteosarcoma risk. Cancer 2018, 124, 3742–3752. [CrossRef]
4. Sadykova, L.R.; Ntekim, A.I.; Muyangwa-Semenova, M.; Rutland, C.S.; Jeyapalan, J.N.; Blatt, N.; Rizvanov, A.A. Epidemiology and Risk Factors of Osteosarcoma. Cancer Investig. 2020, 38, 259–269. [CrossRef] [PubMed]
5. Clark, J.C.; Dass, C.R.; Choong, P.F. A review of clinical and molecular prognostic factors in osteosarcoma. J. Cancer Res. Clin. Oncol. 2008, 134, 281–297. [CrossRef] [PubMed]
6. Pochanugool, L.; Subhadharaphandou, T.; Dhanachai, M.; Hathirat, P.; Sangthawan, D.; Pirabul, R.; Onsanit, S.; Pornpipatpong, N. Prognostic factors among 130 patients with osteosarcoma. Clin. Orthop. Relat. Res. 1997, 345, 206–214. [CrossRef]
7. Taylor, W.F.; Ivins, J.C.; Unni, K.K.; Beabout, J.W.; Golenzer, H.J.; Black, L.E. Prognostic variables in osteosarcoma: A multiinstitutional study. J. Natl. Cancer Inst. 1989, 81, 21–30. [CrossRef]
8. Hudson, M.; Jaffe, M.R.; Jaffe, N.; Ayala, A.; Raymond, A.K.; Carrasco, H.; Wallace, S.; Murray, J.; Robertson, R. Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J. Clin. Oncol. 1990, 8, 1988–1997. [CrossRef] [PubMed]
9. Meyer, W.H.; Schell, M.J.; Kumar, A.P.; Rao, B.N.; Green, A.A.; Champion, J.; Pratt, C.B. Thoracotomy for pulmonary metastatic osteosarcoma: An analysis of prognostic indicators of survival. Cancer 1987, 59, 374–379. [CrossRef]
10. Yang, J.; Yang, D.; Cogdell, D.; Du, X.; Li, H.; Pang, Y.; Sun, Y.; Hu, L.; Sun, B.; Trent, J.; et al. APEX1 gene amplification and its protein overexpression in osteosarcoma: Correlation with recurrence, metastasis, and survival. Technol. Cancer Res. Treat. 2010, 9, 161–169. [CrossRef]
11. Kubista, B.; Klinglmueller, F.; Bilban, M.; Pfeiffer, M.; Lass, R.; Giurea, A.; Funovics, P.T.; Toma, C.; Dominkus, M.; Kotz, R.; et al. Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma. Int. Orthop. 2011, 35, 401–411. [CrossRef] [PubMed]
12. Fuchs, B.; Pritchard, D.J. Etiology of osteosarcoma. Clin. Orthop. Relat. Res. 2002, 397, 40–52. [CrossRef]
13. Tucker, M.A.; D’Angio, G.J.; Boice, J.D.; Strong, L.C.; Li, F.P.; Stovall, M.; Stone, B.J.; Green, D.M.; Lombardi, F.; Newton, W. Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J Med. 1987, 317, 588–593. [CrossRef] [PubMed]
14. Rosen, G.; Marcove, R.C.; Caparros, B.; Nirenberg, A.; Kosloff, C.; Huvos, A.G. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979, 43, 2163–2177. [CrossRef]
15. Whelan, J.S.; Bielack, S.S.; Marina, N.; Smeland, S.; Jovic, G.; Hook, J.M.; Krailo, M.; Anninga, J.; Butterfass-Bahloul, T.; Böhling, T.; et al. EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Ann. Oncol. 2015, 26, 407–414. [CrossRef]
16. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 781–810. [CrossRef]
17. Okamoto, M.; Udagawa, N.; Uehara, S.; Maeda, K.; Yamashita, T.; Nakamichi, Y.; Kato, H.; Saito, N.; Minami, Y.; Takahashi, N.; et al. Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis. Sci. Rep. 2014, 4, 4493. [CrossRef]
18. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837–1851. [CrossRef]
19. Zhou, H.; Mak, W.; Kalak, R.; Street, J.; Fong-Yee, C.; Zheng, Y.; Dunstan, C.R.; Seibel, M.J. Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 2009, 136, 427–436. [CrossRef] [PubMed]
20. Komori, T. Signaling networks in RUNX2-dependent bone development. J. Cell Biochem. 2011, 112, 750–755. [CrossRef]
21. Komori, T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem. Cell Biol. 2018, 149, 313–323. [CrossRef] [PubMed]
22. Weivoda, M.M.; Oursler, M.J. Developments in sclerostin biology: Regulation of gene expression, mechanisms of action, and physiological functions. Curr. Osteoporos. Rep. 2014, 12, 107–114. [CrossRef]
23. Balemans, W.; Ebeling, M.; Patel, N.; van Hul, E.; Olson, P.; Dioszegi, M.; Lacza, C.; Wuyts, W.; van den Ende, J.; Willems, P.; et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10, 537–543. [CrossRef] [PubMed]
24. Loots, G.G.; Kneissel, M.; Keller, H.; Baptist, M.; Chang, J.; Collette, N.M.; Ovcharenko, D.; Plajzer-Frick, I.; Rubin, E.M. Genomic Deletion of a Long-Range Bone Enhancer Misregulates Sclerostin in Van Buchem Disease. Genome Res. 2005, 15, 928–935. [CrossRef] [PubMed]
25. Gooi, J.H.; Pompolo, S.; Karsdal, M.A.; Kulkarni, N.H.; Kalajzic, I.; McAhren, S.H.M.; Han, B.; Onyia, J.E.; Ho, P.W.M.; Gillespie, M.T.; et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 2010, 46, 1486–1497. [CrossRef]
26. Bellido, T.; Ali, A.A.; Gubrij, I.; Plotkin, L.I.; Fu, Q.; O’Brien, C.A.; Manolagas, S.C.; Jilka, R.L. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146, 4577–4583. [CrossRef]
27. Silvestrini, G.; Ballanti, P.; Leopizzi, M.; Sebastiani, M.; Berni, S.; di Vito, M.; Bonucci, E. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J. Mol. Histol. 2007, 38, 261–269. [CrossRef]
28. Drake, M.T.; Srinivasan, B.; Mödder, U.I.; Peterson, J.M.; McCready, L.K.; Riggs, B.L.; Dwyer, D.; Stolina, M.; Kostenuik, P.; Khosla, S. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J. Clin. Endocrinol. Metab. 2010, 95, 5056–5062. [CrossRef]
29. Robling, A.G.; Niziolek, P.J.; Baldridge, L.A.; Condon, K.W.; Allen, M.R.; Alam, I. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 2008, 283, 5866–5875. [CrossRef]
30. Ardawi, M.S.; Rouzi, A.A.; Qari, M.H. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: A cross-sectional and a longitudinal study. J. Clin. Endocrinol. Metab. 2012, 97, 3691–3699. [CrossRef]
31. Chung, Y.E.; Lee, S.H.; Lee, S.Y.; Kim, S.-Y.; Kim, H.-H.; Mirza, F.S.; Lee, S.-K.; Lorenzo, J.A.; Kim, G.S.; Koh, J.-M. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos. Int. 2012, 23, 1235–1243. [CrossRef]
32. Cosman, F.; Crittenden, D.B.; Adachi, J.D.; Binkley, N.; Czerwinski, E.; Ferrari, S.; Hofbauer, L.C.; Lau, E.; Lewiecki, E.M.; Miyauchi, A.; et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 2016, 375, 1532–1543. [CrossRef] [PubMed]
33. Saag, K.G.; Petersen, J.; Brandi, M.L.; Karaplis, A.C.; Lorentzon, M.; Thomas, T.; Maddox, J.; Fan, M.; Meisner, P.D.; Grauer, A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N. Engl. J. Med. 2017, 377, 1417–1427. [CrossRef]
34. Fabre, S.; Funck-Brentano, T.; Cohen-Solal, M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. J. Clin. Med. 2020, 9, 3439. [CrossRef]
35. Kansara, M.; Tsang, M.; Kodjabachian, L.; Sims, N.A.; Trivett, M.K.; Ehrich, M.; Dobrovic, A.; Slavin, J.; Choong, P.F.; Simmons, P.J.; et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Investig. 2009, 119, 837–851. [CrossRef] [PubMed]
36. Vahle, J.L.; Sato, M.; Long, G.G.; Young, J.K.; Francis, P.C.; Engelhardt, J.A.; Westmore, M.S.; Linda, Y.; Nold, J.B. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 2002, 30, 312–321. [CrossRef] [PubMed]
37. Konsavage, W.M.; Kyler, S.L.; Rennoll, S.A.; Jin, G.; Yochum, G.S. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J. Biol. Chem. 2012, 287, 11730–11739. [CrossRef]
38. Wang, W.; Zhong, W.; Yuan, J.; Yan, C.; Hu, S.; Tong, Y.; Mao, Y.; Hu, T.; Zhang, B.; Song, G. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget 2015, 6, 42276–42289. [CrossRef] [PubMed]
39. Jang, G.B.; Kim, J.Y.; Cho, S.D.; Park, K.S.; Jung, J.Y.; Lee, H.Y.; Hong, I.S.; Nam, J.S. Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci. Rep. 2015, 5, 12465. [CrossRef]
40. Kruck, S.; Eyrich, C.; Scharpf, M.; Sievert, K.D.; Fend, F.; Stenzl, A.; Bedke, J. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int. J. Mol. Sci. 2013, 14, 10944–10957. [CrossRef]
41. Choi, M.Y.; Widhopf, G.F.; Wu, C.C.; Cui, B.; Lao, F.; Sadarangani, A.; Cavagnaro, J.; Prussak, C.; Carson, D.A.; Jamieson, C.; et al. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin. Lymphoma Myeloma Leuk. 2015, 15, S167–S169. [CrossRef]
42. Gang, E.J.; Hsieh, Y.T.; Pham, J.; Zhao, Y.; Nguyen, C.; Huantes, S.; Park, E.; Naing, K.; Klemm, L.; Swaminathan, S.; et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acutelymphoblastic leukemia. Oncogene 2014, 33, 2169–2178. [CrossRef]
43. Gurney, A.; Axelrod, F.; Bond, C.J.; Cain, J.; Chartier, C.; Donigan, L.; Fischer, M.; Chaudhari, A.; Ji, M.; Kapoun, A.M.; et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. USA 2012, 109, 11717–11722. [CrossRef]
44. Jiang, X.; Hao, H.X.; Growney, J.D.; Woolfenden, S.; Bottiglio, C.; Ng, N.; Lu, B.; Hsieh, M.; Bagdasarian, L.; Meyer, R.; et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 2013, 110, 12649–12654. [CrossRef] [PubMed]
45. Khan, A.S.; Hojjat-Farsangi, M.; Daneshmanesh, A.H.; Hansson, L.; Kokhaei, P.; Österborg, A.; Mellstedt, H.; Moshfegh, A. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. Tumour Biol. 2016, 37, 11947–11957. [CrossRef] [PubMed]
46. Le, P.N.; McDermott, J.D.; Jimeno, A. Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol. Ther. 2015, 146, 1–11. [CrossRef]
47. Nielsen, T.O.; Poulin, N.M.; Ladanyi, M. Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015, 5, 124–134. [CrossRef] [PubMed]
48. van de Wetering, M.; Francies, H.E.; Francis, J.M.; Bounova, G.; Iorio, F.; Pronk, A.; van Houdt, W.; van Gorp, J.; Taylor-Weiner, A.; Kester, L.; et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015, 161, 933–945. [CrossRef]
49. Pai, S.G.; Carneiro, B.A.; Mota, J.M.; Costa, R.; Leite, C.A.; Barroso-Sousa, R.; Kaplan, J.B.; Chae, Y.K.; Giles, F.J. Wnt/beta-catenin pathway: Modulating anticancer immune response. J. Hematol. Oncol. 2017, 10, 101. [CrossRef]
50. Crago, A.M.; Chmielecki, J.; Rosenberg, M.; O’Connor, R.; Byrne, C.; Wilder, F.G.; Thorn, K.; Agius, P.; Kuk, D.; Socci, N.D.; et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Gen. Chromosom. Cancer 2015, 54, 606–615. [CrossRef]
51. Giraudet, A.L.; Cassier, P.A.; Iwao-Fukukawa, C.; Garin, G.; Badel, J.N.; Kryza, D.; Chabaud, S.; Gilles-Afchain, L.; Clapisson, G.; Desuzinges, C.; et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer 2018, 18, 646. [CrossRef] [PubMed]
52. Hoang, B.H.; Kubo, T.; Healey, J.H.; Sowers, R.; Mazza, B.; Yang, R.; Huvos, A.G.; Meyers, P.A.; Gorlick, R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int. J. Cancer 2004, 109, 106–111. [CrossRef]
53. Lin, C.H.; Guo, Y.; Ghaffar, S.; McQueen, P.; Pourmorady, J.; Christ, A.; Rooney, K.; Ji, T.; Eskander, R.; Zi, X.; et al. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma 2013, 2013, 147541. [CrossRef] [PubMed]
54. Dieudonné, F.X.; Marion, A.; Marie, P.J.; Modrowski, D. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice. J. Bone Miner. Res. 2012, 27, 2118–2129. [CrossRef] [PubMed]
55. Brunkow, M.E.; Gardner, J.C.; van Ness, J.; Paeper, B.W.; Kovacevich, B.R.; Proll, S.; Skonier, J.E.; Zhao, L.; Sabo, P.J.; Fu, Y.; et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 2001, 68, 577–589. [CrossRef]
56. Li, X.; Zhang, Y.; Kang, H.; Liu, W.; Liu, P.; Zhang, J.; Harris, S.E.; Wu, D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol. Chem. 2005, 280, 19883–19887. [CrossRef]
57. Shen, J.; Meyers, C.A.; Shrestha, S.; Singh, A.; LaChaud, G.; Nguyen, V.; Asatrian, G.; Federman, N.; Bernthal, N.; Eilber, F.C.; et al. Sclerostin expression in skeletal sarcomas. Hum. Pathol. 2016, 58, 24–34. [CrossRef]
58. Inagaki, Y.; Hookway, E.S.; Kashima, T.G.; Munemoto, M.; Tanaka, Y.; Hassan, A.B.; Oppermann, U.; Athanasou, N.A. Sclerostin expression in bone tumours and tumour-like lesions. Histopathology 2016, 69, 470–478. [CrossRef]
59. Zou, J.; Zhang, W.; Li, X.L. Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/β-Catenin Signaling Pathway. Calcif. Tissue Int. 2017, 100, 551–564. [CrossRef] [PubMed]
60. Van Bezooijen, R.L.; Roelen, B.A.; Visser, A.; van der Wee-Pals, L.; de Wilt, E.; Karperien, M.; Hamersma, H.; Papapoulos, S.E.; ten Dijke, P.; Löwik, C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004, 199, 805–814. [CrossRef]
61. Moester, M.J.; Papapoulos, S.E.; Löwik, C.W.; van Bezooijen, R.L. Sclerostin: Current knowledge and future perspectives. Calcif. Tissue Int. 2010, 87, 99–107. [CrossRef] [PubMed]
62. Winkler, D.G.; Sutherland, M.K.; Geoghegan, J.C.; Yu, C.; Hayes, T.; Skonier, J.E.; Shpektor, D.; Jonas, M.; Kovacevich, B.R.; Staehling-Hampton, K.; et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22, 6267–6276. [CrossRef]
63. Hattinger, C.M.; Fanelli, M.; Tavanti, E.; Vella, S.; Ferrari, S.; Picci, P.; Serra, M. Advances in emerging drugs for osteosarcoma. Expert Opin. Emerg. Drugs 2015, 20, 495–514. [CrossRef] [PubMed]
64. Martins-Neves, S.R.; Paiva-Oliveira, D.I.; Wijers-Koster, P.M.; Abrunhosa, A.J.; Fontes-Ribeiro, C.; Bovée, J.V.; Cleton-Jansen, A.M.; Gomes, C.M. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling. Cancer Lett. 2016, 370, 286–295. [CrossRef]
65. Hesse, E.; Schröder, S.; Brandt, D.; Pamperin, J.; Saito, H.; Taipaleenmäki, H. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight 2019, 5, e125543. [CrossRef]
66. Toscani, D.; Bolzoni, M.; Ferretti, M.; Palumbo, C.; Giuliani, N. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy. Front. Immunol. 2018, 9, 2467. [CrossRef]
67. Zhu, M.; Liu, C.; Li, S.; Zhang, S.; Yao, Q.; Song, Q. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep. 2017, 7, 11399. [CrossRef] [PubMed]
68. Delgado-Calle, J.; Anderson, J.; Cregor, M.D.; Condon, K.W.; Kuhstoss, S.A.; Plotkin, L.I.; Bellido, T.; Roodman, G.D. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia 2017, 31, 2686–2694. [CrossRef] [PubMed]
69. McDonald, M.M.; Reagan, M.R.; Youlten, S.E.; Mohanty, S.T.; Seckinger, A.; Terry, R.L.; Pettitt, J.A.; Simic, M.K.; Cheng, T.L.; Morse, A.; et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 2017, 129, 3452–3464. [CrossRef]